Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 32NIH 6NETWORK 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Breast Neoplasms 45Sarcoma 33Lymphoma, Large B-Cell, Diffuse 32Neoplasms 25Lymphoma 20Lymphoma, Non-Hodgkin 19Ovarian Neoplasms 17Lymphoma, Follicular 16Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Lymphoma, B-Cell 11Endometrial Neoplasms 11Recurrence 10Carcinoma, Hepatocellular 8Hodgkin Disease 7Lymphoma, T-Cell, Peripheral 6Hematologic Diseases 6Sarcoma, Kaposi 5Lymphoma, Mantle-Cell 5Leiomyosarcoma 5HIV Infections 5Acquired Immunodeficiency Syndrome 5Multiple Myeloma 4Liposarcoma 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Fallopian Tube Neoplasms 3

Interventions

Rituximab 30ibrutinib 26Bendamustine Hydrochloride 18Cyclophosphamide 17acalabrutinib 14fludarabine 13Lenalidomide 11zanubrutinib 10venetoclax 9Vincristine 7Bortezomib 7pirtobrutinib 5brexucabtagene autoleucel 5Prednisone 5Doxorubicin 5temsirolimus 4parsaclisib 4aflibercept 4Gemcitabine 4ublituximab 3orelabrutinib 3loncastuximab tesirine 3idelalisib 3ibritumomab tiuxetan 3Sensitivity and Specificity 3Antigens, CD19 3tositumomab I-131 2tazemetostat 2pembrolizumab 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Mantle-Cell × Doxorubicin × Clear all
NCT06564038 2026-05-14

Soundtrack-E

AstraZeneca

Phase 1/2 Recruiting
408 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05934097 2023-07-06

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Fate Therapeutics

Phase 1 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00722137 2018-07-12

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Takeda

Phase 3 Completed
487 enrolled 20 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT00877006 2018-02-05

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed
447 enrolled 24 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT00022945 2005-06-24

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Corixa Corporation

Phase 2 Completed
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡